A new type of prostate cancer screening test from AnalizaDx showed promise and a higher sensitivity than the leading method of detecting the disease, according to new research. AnalizaDx’s prostate cancer test could represent “a major advance” in diagnosing the disease according to the lead author of the new study, Dr. Mark Stovsky, a urologist […]
Prostate cancer exams don't get better than the current PSA test, which is often criticized for its number of false positives. AnalizaDx is looking for a partner to help it commercialize its technology for prostate cancer and fund research into applying the test to other types of cancer. The company believes its technology will be better at diagnosing prostate cancer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A $10 million public-private deal with Cardinal Health and Ohio State was the largest of several Third Frontier grants for biomedical companies or organizations announced Wednesday. Altogether, imaging companies and organizations received $20 million in funding. Out of eight total grant announcement, Cleveland-area companies were involved in five.